INT131 PPARγ Agonist for NAFLD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nonalcoholic fatty liver disease (NAFLD) and lipodystrophic syndromes are ineffective, and the rapid rise in prevalence of these conditions necessitates new therapeutic options.
Innovation Solution
Administration of the compound 2,4-Dichloro-N-[3,5-dichloro-4-(3-quinolinyloxy)phenyl]benzenesulfonamide, known as INT131, either alone or in combination with vitamin E, to treat NAFLD, lipodystrophic syndromes, or their combination, specifically targeting insulin resistance and associated conditions like liver fibrosis and cirrhosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current pharmaceutical treatments (vitamin C, vitamin E, metformin, etc.) are used for NAFLD, then some metabolic parameters may be improved, but they are ineffective for severe cases and do not address the root cause of insulin resistance
Solution Approach 1:
The patent changes the pharmacological parameter by selecting a specific chemical structure (INT131 with particular molecular weight, logP, and functional groups) that optimizes PPARγ activation. This parameter change enables the compound to effectively treat severe NAFLD cases including NASH and cirrhosis, overcoming the limitations of previous treatments that could not address severe disease stages.
Solution Approach 2:
The patent applies local quality by designing a compound with specific functional groups positioned at particular locations in the molecular structure. The dichloro substituents and quinolinyloxy group are placed at specific positions to enhance binding affinity to PPARγ while maintaining selectivity, thereby achieving reliable treatment effectiveness specifically for insulin resistance-related NAFLD.
2Reliability
If PPARγ agonists are used to treat insulin resistance, then metabolic parameters improve, but edemagenic and lipogenic side effects occur
Solution Approach 1:
The patent applies local quality by introducing specific functional groups (dichloro substituents and quinolinyloxy group) at precise locations in the PPARγ agonist molecule. This localized structural modification enhances the compound's ability to activate beneficial PPARγ pathways while reducing activation of pathways that lead to edemagenic and lipogenic side effects, thereby improving the therapeutic index.
Solution Approach 2:
The patent segments the PPARγ agonist molecule into distinct functional regions: a core structure for PPARγ binding, dichloro substituents for metabolic modulation, and a quinolinyloxy group for selectivity enhancement. This segmentation allows each region to contribute specifically to therapeutic effects while minimizing harmful side effects.
3Reliability
If lifestyle modifications (low-calorie diet and exercise) are implemented, then NAFLD prevention and treatment are most effective, but patient compliance is poor due to voluntary non-compliance, inability to exercise, and long-term diet restriction difficulties
Solution Approach 1:
The patent introduces INT131 as a pharmacological intermediary that mediates the treatment of NAFLD by activating PPARγ pathways. This intermediary compound provides the therapeutic benefits of lifestyle modifications (improved insulin sensitivity, reduced hepatic steatosis) without requiring patients to maintain difficult dietary restrictions or exercise regimens, thereby significantly improving ease of operation and patient compliance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
INT131 effectively reduces the NAFLD activity score, improves liver histology, and alleviates metabolic parameters in patients, demonstrating its therapeutic potential for NAFLD and lipodystrophic syndromes by activating specific PPARγ-dependent pathways without inducing edemagenic or lipogenic effects.
Implementation Method 1
demonstrating its therapeutic potential for NAFLD and lipodystrophic syndromes by activating specific PPARγ-dependent pathways
Data Source
AI summary
The present invention relates to methods for treating a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (NAFLD) and its sequelae, a lipodystrophic syndrome or a combination thereof with the selective PPARγ agonist, INT131 and optionally vitamin E or compositions thereof. NAFLDs that may be treated with methods and compositions of the present invention include, but are not limited to, simple nonalcoholic fatty liver and nonalcoholic steatohepatitis (NASH). Lipodystrophic syndromes that may be treated with the methods and compositions of the present invention include, but are not limited to, generalized lipodystrophy including congenital generalized lipodystrophy and acquired generalized lipodystrophy and/or partial lipodystrophy, including congenital partial lipodystrophy and acquired partial lipodystrophy, all of which may or may not include hyperlipidemia and/or hyperglycemia and may or may not include NAFLD.